60 Degrees Pharmaceuticals Prices $1.0M Private Placement At $1.74 Per Share; Stock Down
60 Degrees Pharmaceuticals (SXTP) said it agreed to a Nasdaq-priced at-the-market private placement. It will sell 574,713 shares (or pre-funded warrants) at $1.74 per share, with Series A warrants and Series B warrants exercisable at $1.49. Gross proceeds are about $1.0 million. Net proceeds will fund working capital. Closing expected around July 31, 2026.
How this was made
The 30-second read
Why it matters
The priced offering provides roughly $1.0M gross proceeds for working capital and general corporate purposes, but it introduces dilution and potential future warrant exercise overhang.
Market read
Traders should focus on dilution math, warrant overhang, and the expected closing date as the next concrete catalyst.
What to watch
Warrant exercise terms and the pre-funded warrant structure can affect effective dilution; actual share impact depends on how many warrants are later exercised.
Background
SXTP is developing medicines for vector-borne diseases and is using an at-the-market private placement under Nasdaq rules.
Ticker impact
60 Degrees Pharmaceuticals announced a $1.74 per-share private placement priced at-the-market, with gross proceeds about $1.0M and warrants issued.
Near-term downside bias around closing and any follow-on dilution expectations; volatility likely elevated given microcap scale.
The article discloses a priced equity issuance plus two warrant tranches, which typically increases share count and can cap upside until capital is deployed or financing terms are digested by the market.
Market effects
Microcap biotech financing conditions and warrant structures can influence sentiment across small vector-borne disease drug developers.
Primarily US microcap sentiment; limited broader regional spillover expected.
Low global relevance given small gross proceeds and company-specific financing.
Counterpoint
If the company’s working-capital need is urgent, the financing could reduce near-term solvency risk, which can offset dilution fears.
Key entities
- company60 Degrees Pharmaceuticals, Inc.
Subject of the private placement announcement and warrant issuance.
- financial_advisorH.C. Wainwright & Co.
Exclusive placement agent for the offering.
